title: Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer.
abstract: OBJECTIVE
  The aim of this study was to determine if p53 status, assessed before intravesical bacillus Calmette-Guerin (BCG) therapy, can predict clinical outcome in a high risk population of patients with stage T1, grade G3 bladder cancer and if it can be used to select patients responsive to therapy.
  
  
  METHODS
  After complete transurethral resection 35 patients with T1G3 bladder carcinoma received 6 weekly instillations of BCG and nonresponsive patients received a second course. After treatment cystoscopy and randomized biopsies of the bladder mucosa were performed. Pathologists had sufficient material to perform immunomarking in 25 cases using the peroxidase-antiperoxidase technique with antiprotein monoclonal antibody p53. The results were expressed in percentage of marked nuclei. We established 5% increment thresholds from 0 to 60%. Contingent tables were established, and chi-square and Fisher's exact test were performed for each 5% threshold.
  
  
  RESULTS
  Median followup was 51.3 months (range 25 to 144). Of the 25 patients 8 (32%) did not respond to BCG therapy and 17 (68%) did. Immunomarkings were not statistically different between BCG responsive and nonresponsive patients for 0, 5, 10, 20, 35, 40, 45, 55 and 65 thresholds. Chi-square and Fisher's exact test were 0.91 and 0.83, 0.40 and 0.20, 0.58 and 0.29, 0.96 and 0.81, 0.80 and 0.88, 0.67 and 0.73, 0.91 and 0.83, 0.80 and 0.38, 0.69 and 0.32, respectively.
  
  
  CONCLUSIONS
  Our results indicate that the percentage of p53 immunomarked cell cannot currently be used to predict clinical response to BCG therapy and, therefore, p53 over expression is not a viable indicator of T1G3 recurrence when using this treatment.
authors.affiliation: Department of Urology, Foch Hospital, Suresnes and René Huguenin Center, St. Cloud, France.
authors.forename: T
authors.initials: T
authors.lastname: Lebret
authors.forename: V
authors.initials: V
authors.lastname: Becette
authors.forename: M
authors.initials: M
authors.lastname: Barbagelatta
authors.forename: J M
authors.initials: JM
authors.lastname: Hervé
authors.forename: F
authors.initials: F
authors.lastname: Gaudez
authors.forename: P
authors.initials: P
authors.lastname: Barré
authors.forename: P M
authors.initials: PM
authors.lastname: Lugagne
authors.forename: H
authors.initials: H
authors.lastname: Botto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use*; D015415:Biomarkers; D002295:Carcinoma, Transitional Cell / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*
chemical_list: D001500:BCG Vaccine; D015415:Biomarkers; D016159:Tumor Suppressor Protein p53